Catalyst Dossier · compiled by CeliA 🧫

GE HealthCare Technologies Inc. (GEHC)

X-Ray Apparatus & Tubes & Related Irradiation Apparatus · market cap $28.0B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-29

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

GE HealthCare Technologies (GEHC) is a large-cap U.S. health technology company with ~$20.6B in annual revenue, operating across medical imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics. The company carries a meaningful pipeline of radiopharmaceutical and diagnostic imaging agents — most notably PET MPI and Flurpiridaz for CAD in Phase 3 — alongside a net debt position of ~$7.9B and a $27.6B market cap at ~$60.64/share.

The catalyst path

2026-07-29Earningsimp 5/10
2026-12-15 (est.)Phase 2 · Regadenosonimp 7/10

Pipeline

Asset	Phase	Indication
Flurpiridaz (18F) Injection	Phase 2	Coronary Artery Disease (CAD)
PET MPI	Phase 3	Coronary Artery Disease (CAD)
SPECT	Phase 3	Parkinson Disease
[18F]Flutemetamol	Phase 3	Alzheimer's Disease
GE-145	Phase 2	Chronic Renal Insufficiency
DaTSCAN™ Ioflupane (123I) Injection	Phase 3	Parkinsonian Syndrome
Regadenoson	Phase 2	Myocardial Ischemia
123I-mIBG (meta-iodobenzylguanidine)	Phase 3	Heart Failure, Congestive
Ioforminol 160 mgI/mL	Phase 2	Healthy
GE-145 (AN113111) Injection	Phase 2	Healthy
DatSCAN	Phase 3	Lewy Body Dementia
Fluciclatide Injection	Phase 2	Solid Tumors
Fluciclatide Injection - (AH111585 (F18))	Phase 2	High-grade Glioma
Sonazoid™	Phase 3	Liver Lesions
AH110690 (18F) Injection	Phase 2	Alzheimer's Disease
Gadodiamide Injection	Phase 3	Aorto-iliac Stenosis
[18F] Flutemetamol	Phase 3	Normal Pressure Hydrocephalus
Flutemetamol (18F) Injection	Phase 3	Mild Cognitive Impairment

Price & technical context

3-month

-8.9%

6-month

-22.0%

12-month

-14.6%

52-wk range

$59.48–$88.16

vs 50-day MA

+1.5%

vs 200-day MA

-12.5%

Realized vol

33.6%

Max drawdown

-37.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GEHC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.